Table 1: Classification of ADHD According to the DSM-V and ICD-10-CM
Table 2: Symptoms of ADHD
Table 3: Prognosis and Risks Associated with ADHD
Table 4: Risk Factors and Comorbidities for ADHD
Table 5: 7MM, Sources of Epidemiological Data Used to Forecast Diagnosed Prevalent Cases of ADHD
Table 6: 7MM, Sources of Epidemiological Data Used to Forecast Diagnosed Prevalent Cases of ADHD by Subtype, Ages 3?17 Years
Table 7: 7MM, Sources of Epidemiological Data Used to Forecast Diagnosed Prevalent Cases of ADHD by Subtype, Ages =18 Years
Table 8: 7MM, Sources Not Used in Epidemiological Analysis of ADHD
Table 9: 7MM, Diagnosed Prevalent Cases of ADHD, Both Sexes, Ages =3 Years, Select Years, 2014–2024
Table 10: 7MM, Age-Specific Diagnosed Prevalent Cases of ADHD, Both Sexes, N (Row%), 2014
Table 11: 7MM, Sex-Specific Diagnosed Prevalent Cases of ADHD, Ages =3 Years, N (Row %), 2014
Table 12: 7MM, Diagnosed Prevalent Cases of ADHD, by Subtype, Ages 3–17 Years, Children and Adolescents, N (Row %), 2014
Table 13: 7MM, Diagnosed Prevalent Cases of ADHD, by Subtype, Ages =18 Years, Adults, N (Row %), 2014
Table 14: Rating Scales Used for ADHD
Table 15: Treatment Guidelines for Disease ADHD
Table 16: Most Prescribed Drugs for ADHD by Class in the Global Markets, 2014
Table 17: Country Profile – US
Table 18: Country Profile – 5EU
Table 19: Country Profile – Japan
Table 20: Leading Treatments for ADHD, 2015
Table 21: Product Profile — Dextroamphetamine
Table 22: Dextroamphetamine SWOT Analysis, 2015
Table 23: Global Sales Forecasts ($m) for Dextroamphetamine, 2014–2024
Table 24: Product Profile – Desoxyn
Table 25: Desoxyn SWOT Analysis, 2015
Table 26: Global Sales Forecasts ($m) for Desoxyn, 2014–2024
Table 27: Product Profile – Adderall XR
Table 28: Adderall XR SWOT Analysis, 2015
Table 29: Global Sales Forecasts ($m) for Adderall XR, 2014–2024
Table 30: Product Profile – Vyvanse
Table 31: Vyvanse SWOT Analysis, 2015
Table 32: Global Sales Forecasts ($m) for Vyvanse, 2014–2024
Table 33: Product Profile – Dyanavel XR
Table 34: Dyanavel SWOT Analysis, 2015
Table 35: Global Sales Forecasts ($m) for Dyanavel XR, 2014–2024
Table 36: Product Profile – Adzenys XR-ODT
Table 37: Adzenys XR-ODT SWOT Analysis, 2015
Table 38: Global Sales Forecasts ($m) for Adzenys XR-ODT, 2014–2024
Table 39: Product Profile – Ritalin LA
Table 40: Ritalin LA SWOT Analysis, 2015
Table 41: Global Sales Forecasts ($m) for Ritalin LA, 2014–2024
Table 42: Product Profile – Concerta
Table 43: Concerta SWOT Analysis, 2015
Table 44: Global Sales Forecasts ($m) for Concerta, 2014–2024
Table 45: Product Profile – Medikinet XL
Table 46: Medikinet SWOT Analysis, 2015
Table 47: Global Sales Forecasts ($m) for Medikinet XL, 2014–2024
Table 48: Product Profile – Metadate CD
Table 49: Incidence of TEAEs in a Pool of 3–4 Week Clinical Trials – Metadate CD
Table 50: Metadate CD SWOT Analysis, 2015
Table 51: Global Sales Forecasts ($m) for Metadate CD, 2014–2024
Table 52: Product Profile – Methylin
Table 53: Methylin SWOT Analysis, 2015
Table 54: Global Sales Forecasts ($m) for Methylin, 2014–2024
Table 55: Product Profile – Focalin
Table 56: TEAEs – Focalin
Table 57: TEAEs – Focalin XR
Table 58: Focalin SWOT Analysis, 2015
Table 59: Global Sales Forecasts ($m) for Focalin and Focalin XR, 2014–2024
Table 60: Product Profile – Daytrana
Table 61: Daytrana SWOT Analysis, 2015
Table 62: Global Sales Forecasts ($m) for Daytrana, 2014–2024
Table 63: Product Profile – Quillivant XR
Table 64: Quillichew Primary Efficacy Result
Table 65: Quillivant XR SWOT Analysis, 2015
Table 66: Global Sales Forecasts ($m) for Quillivant XR/Quillichew, 2014–2024
Table 67: Product Profile – Aptensio XR
Table 68: Summary of the Parallel Group Study – Aptensio XR
Table 69: Aptensio XR SWOT Analysis, 2015
Table 70: Global Sales Forecasts ($m) for Aptensio XR, 2014–2024
Table 71: Product Profile – Strattera
Table 72: Acute and Maintenance Efficacy Studies – Strattera
Table 73: Common TEAEs reported in acute trials in children and adolescents – Strattera
Table 74: Common TEAEs reported in acute trials in adults – Strattera
Table 75: Strattera SWOT Analysis, 2015
Table 76: Global Sales Forecasts ($m) for Strattera, 2014–2024
Table 77: Product Profile – Intuniv
Table 78: Fixed Dose Studies– Intuniv
Table 79: Intuniv SWOT Analysis, 2015
Table 80: Global Sales Forecasts ($m) for Intuniv, 2014–2024
Table 81: Product Profile – Kapvay
Table 82: Kapvay SWOT Analysis, 2015
Table 83: Global Sales Forecasts ($m) for Kapvay, 2014–2024
Table 84: Unmet Need and Opportunity in ADHD
Table 85: Drugs in Development, 2016
Table 86: Comparison of Therapeutic Classes in Development for ADHD, 2014–2024
Table 87: Product Profile – Liquid Amphetamine XR, NT-0201
Table 88: NT-0201 SWOT Analysis, 2015
Table 89: Global Sales Forecasts ($m) for NT-0201, 2014–2024
Table 90: Product Profile – Triple-Bead Mixed Amphetamine Salts (SHP-465)
Table 91: SHP-465 SWOT Analysis, 2015
Table 92: Global Sales Forecasts ($m) for SHP-465, 2014–2024
Table 93: Product Profile – HLD-100
Table 94: HLD-100 SWOT Analysis, 2015
Table 95: Global Sales Forecasts ($m) for HLD-100, 2014–2024
Table 96: Product Profile – Dextroamphetamine Transdermal Patch
Table 97: Dextroamphetamine Transdermal Patch SWOT Analysis, 2015
Table 98: Global Sales Forecasts ($m) for ATS, 2014–2024
Table 99: Product Profile – Cotempla XR-ODT
Table 100: Cotempla XR-ODT SWOT Analysis, 2015
Table 101: Global Sales Forecasts ($m) for Cotempla XR-ODT, 2014–2024
Table 102: Product Profile – Benjorna
Table 103: Benjorna SWOT Analysis, 2015
Table 104: Global Sales Forecasts ($m) for Benjorna, 2014–2024
Table 105: Product Profile – Dasotraline
Table 106: Dasotraline SWOT Analysis, 2015
Table 107: Global Sales Forecasts ($m) for dasotraline, 2014–2024
Table 108: Product Profile – Centanafadine SR
Table 109: Centanafadine SR SWOT Analysis, 2015
Table 110: Global Sales Forecasts ($m) for centanafadine SR, 2014–2024
Table 111: Product Profile – SPN-810
Table 112: SPN-810 SWOT Analysis, 2015
Table 113: Global Sales Forecasts ($m) for SPN-810, 2014–2024
Table 114: Product Profile – Viloxazine
Table 115: Viloxazine SWOT Analysis, 2015
Table 116: Global Sales Forecasts ($m) for Pipeline Viloxazine, 2014–2024
Table 117: Product Profile – Metadoxine ER
Table 118: Metadoxine ER SWOT Analysis, 2015
Table 119: Global Sales Forecasts ($m) for Metadoxine ER, 2014–2024
Table 120: Product Profile – Eltoprazine
Table 121: Eltoprazine SWOT Analysis, 2015
Table 122: Global Sales Forecasts ($m) for Eltoprazine, 2014–2024
Table 123: Product Profile – CM-4612
Table 124: CM-4612 SWOT Analysis, 2015
Table 125: Global Sales Forecasts ($m) for CM-4612, 2014–2024
Table 126: Drugs in Development, 2016
Table 127: Key Companies in the ADHD Market in the 7MM, 2014
Table 128: Shire’s ADHD Portfolio Assessment, 2015
Table 129: Novartis’ ADHD Portfolio Assessment, 2015
Table 130: Janssen’s ADHD Portfolio Assessment, 2015
Table 131: Eli Lilly’s ADHD Portfolio Assessment, 2015
Table 132: Pfizer/Tris Pharma’s ADHD Portfolio Assessment, 2015
Table 133: Highland Therapeutics’ ADHD Portfolio Assessment, 2016
Table 134: Global Sales Forecasts ($m) for ADHD, 2014–2024
Table 135: ADHD Market – Global Drivers and Barriers, 2014?2024
Table 136: Sales Forecasts ($m) for ADHD in the US, 2014–2024
Table 137: Key Events Impacting Sales for ADHD in the US, 2014–2024
Table 138: ADHD Market – Drivers and Barriers in the US, 2014?2024
Table 139: Sales Forecasts ($m) for ADHD in the 5EU, 2014–2024
Table 140: Key Events Impacting Sales for ADHD in the 5EU, 2014–2024
Table 141: ADHD Market – Drivers and Barriers in the 5EU, 2014?2024
Table 142: Sales Forecasts ($m) for ADHD in Japan, 2014–2024
Table 143: Key Events Impacting Sales for ADHD in Japan, 2014–2024
Table 144: ADHD Market – Drivers and Barriers in Japan, 2014?2024
Table 145: Key ADHD Launch Dates
Table 146: Key ADHD Patent Expiries
Table 147: High-Prescribing Physicians (Non-KOLs) Surveyed, By Country, 2016